Loading
Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.
Klaus Pantel is Director of the Institute of Tumor Biology at Universitätsklinikum Hamburg-Eppendorf. His specialisms are liquid biopsy, circulating tumour cells and minimal residual disease. His work on disseminated and circulating tumour cells established liquid biopsy as a research discipline, and he coordinated the European CANCER-ID consortium. His Nature Reviews Clinical Oncology paper reviewed liquid biopsy and minimal residual disease, and their implications for cure. He is a pioneer of circulating tumour cell research, working across circulating tumour DNA and molecular residual disease testing. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Liquid biopsy and minimal residual disease: latest advances and implications for cure | Nature Reviews Clinical Oncology | 2019 |
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).